Corcept Therapeutics' Upcoming FDA Decision: Is A CRL Likely?

Benzinga_recent_news

2025/12/23

Are There Red Flags in the Trial Results? Introduction: Corcept Therapeutics' (CORT) Relacorilant is currently under FDA review with a PDUFA target date of December 30, 2025. This upcoming regulatory ...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2593431913"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2593431913\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2593431913?lang=zh_TW&edition=fundamental","thumbnail":"https://static.tigerbbs.com//next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=240?op=imageView2&mode=2&width=256&height=256&quality=70&format=png","is_english":true,"pubTime":"2025-12-23 00:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593431913","market":"hk","top_or_hot":-1,"title":"Corcept Therapeutics' Upcoming FDA Decision: Is A CRL Likely?","media":"Benzinga_recent_news","content":"<div>\n<p>Are There Red Flags in the Trial Results?\nIntroduction:\nCorcept Therapeutics' (CORT) Relacorilant is currently under FDA review with a PDUFA target date of December 30, 2025. This upcoming regulatory ...</p>\n\n<a href=\"https://www.benzinga.com/Opinion/25/12/49541761/corcept-therapeutics-upcoming-fda-decision-is-a-crl-likely\">网页链接</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Corcept Therapeutics' Upcoming FDA Decision: Is A CRL Likely?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorcept Therapeutics' Upcoming FDA Decision: Is A CRL Likely?\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Benzinga_recent_news</strong><span class=\"h-time small\">2025-12-23 00:41</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>Are There Red Flags in the Trial Results?\nIntroduction:\nCorcept Therapeutics' (CORT) Relacorilant is currently under FDA review with a PDUFA target date of December 30, 2025. This upcoming regulatory ...</p>\n\n<a href=\"https://www.benzinga.com/Opinion/25/12/49541761/corcept-therapeutics-upcoming-fda-decision-is-a-crl-likely\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://www.benzinga.com/Opinion/25/12/49541761/corcept-therapeutics-upcoming-fda-decision-is-a-crl-likely\">Benzinga_recent_news</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票月供概念","start_time":0,"source_url":"https://www.benzinga.com/Opinion/25/12/49541761/corcept-therapeutics-upcoming-fda-decision-is-a-crl-likely","article_id":"2593431913","we_media_id":null,"thumbnails":["https://static.tigerbbs.com//next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=240?op=imageView2&mode=2&width=256&height=256&quality=70&format=png"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/Opinion/25/12/49541761/corcept-therapeutics-upcoming-fda-decision-is-a-crl-likely","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2593431913","pubTimestamp":1766421660,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Are There Red Flags in the Trial Results?Corcept Therapeutics'  Relacorilant is currently under FDA review with a PDUFA target date of December 30, 2025. This upcoming regulatory milestone is financially pivotal for Corcept to reduce sole reliance on Korlym for revenue generation and shift towards a multi-asset profitability company. If Relacirilant's PDUFA outcome is unfavorable, it would significantly affect Corcept's valuation, since they will have no other pre-registration drug expected to reach approval in the next 3-5 years.Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga’s reporting and has not been edited for content or accuracy.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","CORT":"Corcept医疗","LU0566484027.USD":"安本美国小盘成长股","BK4532":"文艺复兴科技持仓","BK4121":"生命科学工具和服务","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","BK4530":"医药外包概念","IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","BK4007":"制药","CRL":"查尔斯河","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","BK4588":"碎股","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC"},"translate_title":"Corcept Therapeutics即将做出的FDA决定：CRL可能吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRL":1.5,"CORT":1.5},"content_text":"Are There Red Flags in the Trial Results?\nIntroduction:\nCorcept Therapeutics' (CORT) Relacorilant is currently under FDA review with a PDUFA target date of December 30, 2025. This upcoming regulatory milestone is financially pivotal for Corcept to reduce sole reliance on Korlym for revenue generation and shift towards a multi-asset profitability company.  If Relacirilant's PDUFA outcome is unfavorable, it would significantly affect Corcept's valuation, since they will have no other pre-registration drug expected to reach approval in the next 3-5 years.\nClinical & Regulatory Assessment:\nRelacorilant, developed by Corcept Therapeutics (NASDAQ:CORT), is a selective glucocorticoid receptor (GR) antagonist designed to control hypercortisolism symptoms in endogenous Cushing's syndrome.  Relacorilant's NDA is primarily supported by data from two Phase 3 trials: GRACE and GRADIENT.\nIn the GRACE trial, which enrolled patients with endogenous Cushing's syndrome of all etiologies, relacorilant met its primary endpoint where patients switched to placebo had a significantly higher risk of losing hypertension control. Whereas in the GRADIENT trial, which enrolled patients with adrenal-origin Cushing's syndrome, relacorilant did not met its primary endpoint to reduce mean systolic blood pressure. This suggests that relacorilant might be more effective in endogenous Cushing syndrome patients with non-adrenal atieology, which is the majority of them. But given that the indication for NDA is all endogenous Cushing Syndrome patients (including patients with adrenal adenoma), the failure to meet primary endpoint in GRADIENT trial might increase the risk of getting complete response letter for this application. Despite this, the safety profile of relacorilant is favorable.\nFinancial position outlook:\nWith a market capitalization of  8.9 billion, Corcept Therapeutics holds a strong liquidity position with no long-term debt. Although both R&D and SG&A have increased in recent quarters, there is nothing alarming since it is consistent with company's expanding clinical activities and commercialization preparation prior to Relacorliant PDUFA event.\nCorcept Therapeutics' share outstanding remained basically unchanged and there is no sign of imminent dilution due to urgent equity financing. This is largely attributable to increase in revenue from further commercialization of their first approved drug Korlym, which allows the company to fund pipeline development. Overall, Corcept is currently in a solid financial position.\nBenzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga’s reporting and has not been edited for content or accuracy.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}